NCT06395103

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE1, PHASE2

Sponsor: Merck Sharp & Dohme LLC

Condition: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Signal summary

Status signal: Low Signal

Timeline signals: long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: None

Stopped reason

No stop reason available in the current public record.